ClinicalTrials.gg
Enrolling by invitationNCT05935644ORCHID-MiamiUpdated Oct 29, 2026

ORCHID: An Online Intervention for Persons With HIV (Miami)

An interventional study of ORCHID in HIV/AIDS and HPV Infection, sponsored by University of Miami. Enrolling by invitation at 1 site in United States. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by University of Miami · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Now Enrolling by invitationPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 24 studies in Acquired Immunodeficiency Syndrome by University of Miami — 6 open to participants now, 7 under way, none of them phase 3. Acquired Immunodeficiency Syndrome · University of Miami.

Planned enrollment
14th of 23
30 · median 47
Started
2024
with 4 others
No phase
22 of 24
6 open now
Registered
18th of 24
by date

Among the 24 studies in Acquired Immunodeficiency Syndrome by University of Miami, this one is the 14th largest by planned enrollment of the 23 interventional ones that give a count, is one of 5 that started in 2024, is one of 22 with no phase, and was the 18th registered.

Acquired Immunodeficiency Syndrome

3,039 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.

Browse Acquired Immunodeficiency Syndrome studies →

Open to participants now

6 of the 24 studies in Acquired Immunodeficiency Syndrome by University of Miami are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 197 Acquired Immunodeficiency Syndrome studies recruiting now, 117 (59%) set no upper age limit and 67 (34%) stop at 75 or younger; 43 take children under 18; 68 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Acquired Immunodeficiency Syndrome by University of Miami, or all of them as a file.
02

Study summary

The purpose of this research is to test ORCHID (Optimizing Resilience \& Coping with HIV through Internet Delivery), a skills-building intervention that improves mental health status for persons with HIV, who are at-risk for falling out of care.

03

Conditions studied

  • HIV/AIDS
  • HPV Infection

Keywords

  • depression
  • mobile applications
  • cortisol levels
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cis-gender women,
  2. Receiving (HIV) care at the University of Miami Women's HIV Service,
  3. Recent history (12-month) of cervical or anal dysplasia or human papilloma virus (HPV) positivity; AND a recent (12-month) history of one or more of the following:

i) drug use (alcohol, tobacco products, marijuana, illicit drugs) or ii) depression or iii) psychiatric condition (anxiety, post-traumatic stress disorder (PTSD)) or iv) unsuppressed HIV viral load d. All life stages - pregnant, non-pregnant, pre/

Exclusion criteria

Exclusion Criteria:

  1. Under 18
  2. Not able to read/write English at the 6th grade level
  3. Cognitively impaired adults (as documented in medical records)
  4. Debilitating psychiatric condition (e.g. schizophrenia/bi-polar/psychotic disorders)
  5. Prisoners
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    ORCHID Group

    Participants in the ORCHID group will receive an online intervention that improves depressive symptoms and positive affect (emotions) for clinic-based persons living with HIV, for up to 6 months.

    Behavioral: ORCHID

Interventions

  • BehavioralORCHID

    The intervention includes 8 modules, which are delivered online, approximately 30 minutes per session, and participants will engage a minimum of once per week. Participants may also meet online or in-person with a navigator, up to 4 times.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants who Complete ORCHID

    Average across all participants of the proportion of participants who login to all 8 ORCHID intervention sessions, calculated as total number of sessions opened (0-8) divided by 8.

    Time frame: Up to 6 months

Secondary outcomes

  1. Depression as measured by Patient Health Questionnaire (PHQ-9)

    Depression will be measured using the PHQ-9 (range 0 to 27), higher scores indicate higher levels of depressive symptoms

    Time frame: Up to 6 months

  2. Positive Affect as measured by Positive and Negative Affect Schedule (PANAS)

    Positive affect will be measured using the PANAS, range is 10 to 50, higher scores indicate higher levels of positive emotions.

    Time frame: Up to 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Apr 2027, 30 months after the start.

Of 642 non-industry interventional studies with no phase under Acquired Immunodeficiency Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 30 months is close to that.

Counting every sponsor, half of 648 studies reached it within 29 months; a quarter within 17 and three quarters within 45.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 29, 2026: primary completion Oct 2026 → Apr 2027 and completion Oct 2026 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 7, 2023
StartActual
Oct 1, 2024
Primary completionEst.
Apr 27, 2027was Oct 2026
CompletionEst.
Apr 30, 2027was Oct 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Enrolling by invitation Reason for stopping removed
changed Oct 29, 2026
Primary completion
Oct 27, 2026→Apr 27, 2027
Oct 29, 2026
Study completion
Oct 31, 2026→Apr 30, 2027
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Suspended→Enrolling by invitation
    Why stopped Reason for stopping removed
    Primary completion Oct 27, 2026→Apr 27, 2027
    Study completion Oct 31, 2026→Apr 30, 2027
    + 2 other changes: verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05935644
Responsible party
Lunthita M. Duthely (Research Associate Professor, University of Miami) — Principal investigator
First posted
Jul 7, 2023
Start date
Oct 1, 2024
Primary completion
Apr 27, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Lunthita M Duthely, Ed.D.
principal investigator · University of Miami

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion